Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects.

Journal of virology

Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD.
PMID: 34668774
J Virol. 2021 Oct 20;JVI0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20.

Mutations in the spike protein of SARS-CoV-2 variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in several spike regions. To help predict...

Cite
Lusvarghi S, Wang W, Herrup R, et al. Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. J Virol. 2021;JVI0111021doi: 10.1128/JVI.01110-21.
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021). Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. Journal of virology, JVI0111021. https://doi.org/10.1128/JVI.01110-21
Lusvarghi, Sabrina, et al. "Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects." Journal of virology vol. (2021): JVI0111021. doi: https://doi.org/10.1128/JVI.01110-21
Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD. Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. J Virol. 2021 Oct 20;JVI0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20. PMID: 34668774.
Copy Download .nbib Format: NLM
BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance.

Cancers

Ashar YV, Zhou J, Gupta P, Teng QX, Lei ZN, Reznik SE, Lusvarghi S, Wurpel J, Ambudkar SV, Chen ZS.
PMID: 32899268
Cancers (Basel). 2020 Sep 03;12(9). doi: 10.3390/cancers12092502.

Multidrug resistance (MDR) associated with the overexpression of ABC transporters is one of the key causes of chemotherapy failure. Various compounds blocking the function and/or downregulating the expression of these transporters have been developed over the last few decades....

Cite
Ashar YV, Zhou J, Gupta P, et al. BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092502.
Ashar, Y. V., Zhou, J., Gupta, P., Teng, Q. X., Lei, Z. N., Reznik, S. E., Lusvarghi, S., Wurpel, J., Ambudkar, S. V., & Chen, Z. S. (2020). BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers, 12(9), . https://doi.org/10.3390/cancers12092502
Ashar, Yunali V, et al. "BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092502
Ashar YV, Zhou J, Gupta P, Teng QX, Lei ZN, Reznik SE, Lusvarghi S, Wurpel J, Ambudkar SV, Chen ZS. BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020 Sep 03;12(9). doi: 10.3390/cancers12092502. PMID: 32899268; PMCID: PMC7565406.
Copy Download .nbib Format: NLM
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.

Journal of virology

Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD.
PMID: 34668774
J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20.

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...

Cite
Lusvarghi S, Wang W, Herrup R, et al. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2021;96(1):e0111021doi: 10.1128/JVI.01110-21.
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2022). Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. Journal of virology, 96(1), e0111021. https://doi.org/10.1128/JVI.01110-21
Lusvarghi, Sabrina, et al. "Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects." Journal of virology vol. 96,1 (2022): e0111021. doi: https://doi.org/10.1128/JVI.01110-21
Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20. PMID: 34668774.
Copy Download .nbib Format: NLM
OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance.

Frontiers in pharmacology

Yang Y, Wu ZX, Wang JQ, Teng QX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS, Yang DH.
PMID: 33658942
Front Pharmacol. 2021 Feb 15;12:620874. doi: 10.3389/fphar.2021.620874. eCollection 2021.

OTS964 is a potent T-LAK cell-originated protein kinase (TOPK) inhibitor. Herein, we investigated the interaction of OTS964 and multidrug resistance (MDR)-associated ATP-binding cassette sub-family G member 2 (ABCG2). The cell viability assay indicated that the effect of OTS964 is...

Cite
Yang Y, Wu ZX, Wang JQ, et al. OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Front Pharmacol. 2021;12:620874doi: 10.3389/fphar.2021.620874.
Yang, Y., Wu, Z. X., Wang, J. Q., Teng, Q. X., Lei, Z. N., Lusvarghi, S., Ambudkar, S. V., Chen, Z. S., & Yang, D. H. (2021). OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in pharmacology, 12620874. https://doi.org/10.3389/fphar.2021.620874
Yang, Yuqi, et al. "OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance." Frontiers in pharmacology vol. 12 (2021): 620874. doi: https://doi.org/10.3389/fphar.2021.620874
Yang Y, Wu ZX, Wang JQ, Teng QX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS, Yang DH. OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Front Pharmacol. 2021 Feb 15;12:620874. doi: 10.3389/fphar.2021.620874. eCollection 2021. PMID: 33658942; PMCID: PMC7917255.
Copy Download .nbib Format: NLM
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.

Viruses

Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W.
PMID: 34960755
Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485.

The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve. Here, we compared B.1.617 variants for neutralization...

Cite
Neerukonda SN, Vassell R, Lusvarghi S, et al. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021;13(12)doi: 10.3390/v13122485.
Neerukonda, S. N., Vassell, R., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., & Wang, W. (2021). SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 13(12), . https://doi.org/10.3390/v13122485
Neerukonda, Sabari Nath, et al. "SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122485
Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485. PMID: 34960755; PMCID: PMC8707919.
Copy Download .nbib Format: NLM
MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.

American journal of cancer research

Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.
PMID: 32064159
Am J Cancer Res. 2020 Jan 01;10(1):164-178. eCollection 2020.

The overexpression of one or multiple ATP-binding cassette (ABC) transporters such as ABCB1, ABCC1 or ABCG2 in cancer cells often leads to the development of multidrug resistance phenotype and consequent treatment failure. Therefore, these transporters constitute an important target...

Cite
Wu CP, Lusvarghi S, Tseng PJ, et al. MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Am J Cancer Res. 2020;10(1):164-178
Wu, C. P., Lusvarghi, S., Tseng, P. J., Hsiao, S. H., Huang, Y. H., Hung, T. H., & Ambudkar, S. V. (2020). MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American journal of cancer research, 10(1), 164-178.
Wu, Chung-Pu, et al. "MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs." American journal of cancer research vol. 10,1 (2020): 164-178.
Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. Am J Cancer Res. 2020 Jan 01;10(1):164-178. eCollection 2020. PMID: 32064159; PMCID: PMC7017726.
Copy Download .nbib Format: NLM
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Cancers

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.
PMID: 31940916
Cancers (Basel). 2020 Jan 12;12(1). doi: 10.3390/cancers12010186.

Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in...

Cite
Wu ZX, Yang Y, Teng QX, et al. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020;12(1)doi: 10.3390/cancers12010186.
Wu, Z. X., Yang, Y., Teng, Q. X., Wang, J. Q., Lei, Z. N., Wang, J. Q., Lusvarghi, S., Ambudkar, S. V., Yang, D. H., & Chen, Z. S. (2020). Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 12(1), . https://doi.org/10.3390/cancers12010186
Wu, Zhuo-Xun, et al. "Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance." Cancers vol. 12,1 (2020). doi: https://doi.org/10.3390/cancers12010186
Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020 Jan 12;12(1). doi: 10.3390/cancers12010186. PMID: 31940916; PMCID: PMC7017082.
Copy Download .nbib Format: NLM
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.

Viruses

Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W.
PMID: 34960755
Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485.

The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve. Here, we compared B.1.617 variants for neutralization...

Cite
Neerukonda SN, Vassell R, Lusvarghi S, et al. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021;13(12)doi: 10.3390/v13122485.
Neerukonda, S. N., Vassell, R., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., & Wang, W. (2021). SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 13(12), . https://doi.org/10.3390/v13122485
Neerukonda, Sabari Nath, et al. "SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122485
Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485. PMID: 34960755.
Copy Download .nbib Format: NLM
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.

Journal of virology

Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD.
PMID: 34668774
J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20.

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...

Cite
Lusvarghi S, Wang W, Herrup R, et al. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2021;96(1):e0111021doi: 10.1128/JVI.01110-21.
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2022). Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. Journal of virology, 96(1), e0111021. https://doi.org/10.1128/JVI.01110-21
Lusvarghi, Sabrina, et al. "Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects." Journal of virology vol. 96,1 (2022): e0111021. doi: https://doi.org/10.1128/JVI.01110-21
Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20. PMID: 34668774.
Copy Download .nbib Format: NLM
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.

Journal of virology

Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD.
PMID: 34668774
J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20.

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...

Cite
Lusvarghi S, Wang W, Herrup R, et al. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2021;96(1):e0111021doi: 10.1128/JVI.01110-21.
Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2022). Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. Journal of virology, 96(1), e0111021. https://doi.org/10.1128/JVI.01110-21
Lusvarghi, Sabrina, et al. "Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects." Journal of virology vol. 96,1 (2022): e0111021. doi: https://doi.org/10.1128/JVI.01110-21
Lusvarghi S, Wang W, Herrup R, Neerukonda SN, Vassell R, Bentley L, Eakin AE, Erlandson KJ, Weiss CD. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2022 Jan 12;96(1):e0111021. doi: 10.1128/JVI.01110-21. Epub 2021 Oct 20. PMID: 34668774.
Copy Download .nbib Format: NLM
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.

Viruses

Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W.
PMID: 34960755
Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485.

The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve. Here, we compared B.1.617 variants for neutralization...

Cite
Neerukonda SN, Vassell R, Lusvarghi S, et al. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021;13(12)doi: 10.3390/v13122485.
Neerukonda, S. N., Vassell, R., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., & Wang, W. (2021). SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 13(12), . https://doi.org/10.3390/v13122485
Neerukonda, Sabari Nath, et al. "SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity." Viruses vol. 13,12 (2021). doi: https://doi.org/10.3390/v13122485
Neerukonda SN, Vassell R, Lusvarghi S, Wang R, Echegaray F, Bentley L, Eakin AE, Erlandson KJ, Katzelnick LC, Weiss CD, Wang W. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses. 2021 Dec 11;13(12). doi: 10.3390/v13122485. PMID: 34960755; PMCID: PMC8707919.
Copy Download .nbib Format: NLM
SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.

bioRxiv : the preprint server for biology

Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SAA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD.
PMID: 34981057
bioRxiv. 2021 Dec 28; doi: 10.1101/2021.12.22.473880.

The rapid spread of the highly contagious Omicron variant of SARS-CoV-2 along with its high number of mutations in the spike gene has raised alarm about the effectiveness of current medical countermeasures. To address this concern, we measured neutralizing...

Cite
Lusvarghi S, Pollett SD, Neerukonda SN, et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv. 2021;doi: 10.1101/2021.12.22.473880.
Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., Wang, W., Wang, R., Vassell, R., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., Colombo, C. J., Mody, R., Ewers, E. C., Lalani, T., Ganesan, A., Goguet, E., Hollis-Perry, M., Coggins, S. A. A., Simons, M. P., Katzelnick, L. C., Wang, G., Tribble, D. R., Bentley, L., Eakin, A. E., Broder, C. C., Erlandson, K. J., Laing, E. D., Burgess, T. H., Mitre, E., & Weiss, C. D. (2021). SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.12.22.473880
Lusvarghi, Sabrina, et al. "SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.12.22.473880
Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, Colombo CJ, Mody R, Ewers EC, Lalani T, Ganesan A, Goguet E, Hollis-Perry M, Coggins SAA, Simons MP, Katzelnick LC, Wang G, Tribble DR, Bentley L, Eakin AE, Broder CC, Erlandson KJ, Laing ED, Burgess TH, Mitre E, Weiss CD. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv. 2021 Dec 28; doi: 10.1101/2021.12.22.473880. PMID: 34981057; PMCID: PMC8722594.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries